Class information for:
Level 2: HER 2//TRASTUZUMAB//LAPATINIB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
451 15419 41.4 82%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 3)


ID, lev.
above		 Publications Label for level above
100 72119 HER 2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA

Classes in level below (level 1)


ID, lev. below Publications Label for level below
1882 2371 C ERBB 2//HER 2 NEU//P185
3276 1944 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
3975 1795 IMMUNOGENE//MED MOLEC BIOL SHINJUKU KU//ERBB PROTEINS
4614 1682 NIMOTUZUMAB//H R3//CETUXIMAB
6712 1378 HER 2//HER2 TESTING//POLYSOMY 17
9292 1101 TRANSFORMING GROWTH FACTOR ALPHA//TGF ALPHA//HTGF ALPHA
10741 971 HB EGF//HEPARIN BINDING EGF LIKE GROWTH FACTOR//HEPARIN BINDING EPIDERMAL GROWTH FACTOR LIKE GROWTH FACTOR
11029 948 ANILINOQUINAZOLINE//COMBI MOLECULE//CANC DRUG
11560 907 VCSA1//MK1//UROGASTRONE
13544 765 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2//ADVANCED METASTATIC DISEASE//ANTI EGF RECEPTOR ANTIBODY
17457 535 HER3//NUCLEAR EGFR//EGFR FAMILY
19515 437 BREAST CARCINOMA CELL LINE//BIOTINYLATED EPIDERMAL GROWTH FACTOR//BREAST CANCER BIOPSIES
21995 340 ASTROGLIAL CELL CULTURES//NEUROSTATIN//ERBB1
25024 245 EGF POLYMORPHISM//GEFITINIB THERAPY//INTRON 1 POLYMORPHISM

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 HER 2 Author keyword 658 42% 8% 1215
2 TRASTUZUMAB Author keyword 638 52% 6% 869
3 LAPATINIB Author keyword 218 55% 2% 275
4 EGFR Author keyword 164 17% 6% 858
5 EPIDERMAL GROWTH FACTOR RECEPTOR Author keyword 152 20% 4% 683
6 HER 2 NEU Author keyword 149 39% 2% 297
7 C ERBB 2 Author keyword 145 44% 2% 248
8 PERTUZUMAB Author keyword 121 73% 1% 93
9 HB EGF Author keyword 115 55% 1% 143
10 ERBB2 Author keyword 98 34% 2% 234

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class		 LCSH search Wikipedia search
1 HER 2 658 42% 8% 1215 Search HER+2 Search HER+2
2 TRASTUZUMAB 638 52% 6% 869 Search TRASTUZUMAB Search TRASTUZUMAB
3 LAPATINIB 218 55% 2% 275 Search LAPATINIB Search LAPATINIB
4 EGFR 164 17% 6% 858 Search EGFR Search EGFR
5 EPIDERMAL GROWTH FACTOR RECEPTOR 152 20% 4% 683 Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR
6 HER 2 NEU 149 39% 2% 297 Search HER+2+NEU Search HER+2+NEU
7 C ERBB 2 145 44% 2% 248 Search C+ERBB+2 Search C+ERBB+2
8 PERTUZUMAB 121 73% 1% 93 Search PERTUZUMAB Search PERTUZUMAB
9 HB EGF 115 55% 1% 143 Search HB+EGF Search HB+EGF
10 ERBB2 98 34% 2% 234 Search ERBB2 Search ERBB2

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 NEU ONCOGENE 542 51% 5% 759
2 EGF RECEPTOR 401 25% 9% 1365
3 TRASTUZUMAB 303 33% 5% 763
4 HER 2 300 43% 3% 536
5 GROWTH FACTOR RECEPTOR 254 10% 15% 2330
6 HER 2 NEU 174 37% 2% 373
7 HER 2 NEU GENE AMPLIFICATION 172 73% 1% 130
8 ERBB RECEPTORS 156 45% 2% 264
9 GENE AMPLIFICATION 141 20% 4% 644
10 HER 2 NEU ONCOGENE 141 61% 1% 151

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice 2007 798 70 79%
Untangling the ErbB signalling network 2001 2946 106 58%
HER2-directed therapy: current treatment options for HER2-positive breast cancer 2015 5 82 76%
SIGNAL TRANSDUCTION BY RECEPTORS WITH TYROSINE KINASE-ACTIVITY 1990 4682 85 48%
Treatment of HER2-positive breast cancer: current status and future perspectives 2012 195 125 62%
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 2009 409 123 66%
Targeting HER2 for the Treatment of Breast Cancer 2015 3 82 72%
EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES AND THEIR RECEPTORS IN HUMAN MALIGNANCIES 1995 1666 518 56%
The ErbB/HER family of protein-tyrosine kinases and cancer 2014 55 278 36%
EGF-ERBB signalling: towards the systems level 2006 853 135 47%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MED DEV ONCOL 18 83% 0.1% 10
2 ONCOGENE SCI 18 89% 0.1% 8
3 CANC DRUG 15 73% 0.1% 11
4 MED ONCOL MEDCANC DRUG 14 100% 0.0% 7
5 ENDOCRINE CANC GRP 13 37% 0.2% 28
6 RADIOBIOL MOL ENVIRONM 13 46% 0.1% 21
7 LIVER METASTASIS GRP 11 78% 0.0% 7
8 TUMOR BIOL METASTASIS GRP 9 83% 0.0% 5
9 ONCOPHARMACOL UNIT 9 29% 0.2% 26
10 CANC DRUG MED MED ONCOL 8 100% 0.0% 5

Related classes at same level (level 2)


Rank Relatedness score Related classes
1 0.0000015299 IQGAP1//LRIG1//MIG 6
2 0.0000014625 CHROMATIN SUPRAORGANIZATION//ZNF703//NUCLEAR PHENOTYPES
3 0.0000014398 NON SMALL CELL LUNG CANCER//XRCC1//GEFITINIB
4 0.0000010183 TETRASPANIN//CD9//CD151
5 0.0000010102 BREAST CANCER//ACCELERATED PARTIAL BREAST IRRADIATION//PARTIAL BREAST IRRADIATION
6 0.0000007561 HEPATOCYTE GROWTH FACTOR//C MET//HGF
7 0.0000007125 NEUROCHEM NEUROBIOL//GLIA MATURATION FACTOR//GLIA MATURATION FACTOR GMF
8 0.0000006852 MAMMARY GLAND//MOUSE MAMMARY TUMOR VIRUS//JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
9 0.0000006792 HAND FOOT SYNDROME//RADIATION RECALL//EXTRAVASATION
10 0.0000006378 CHRONIC MYELOID LEUKEMIA//IMATINIB//BCR ABL